Benzimidazoles induce concurrent apoptosis and pyroptosis of human glioblastoma cells via arresting cell cycle (2022)

Peer-Reviewed Study · Ren LW, Li W, Zheng XJ, Liu JY, Yang YH, Li S, Zhang S, Fu WQ, Xiao B, Wang JH, Du GH · January 2022

Ren LW et al., 2022-01: A Chinese group reports that flubendazole, mebendazole and fenbendazole inhibit U87 and U251 glioblastoma cell proliferation at sub-micromolar IC50, arrest cells at G2/M via p53/p21/cyclin B1 and trigger pyroptosis.

When their anti-GBM activity was examined, however, only three benzimidazole compounds, i.e. flubendazole, mebendazole and fenbendazole, potently and dose-dependently inhibited proliferation of U87 and U251 cells with IC50 values below 0.26 μM.

Ren LW et al., 2022-01: A Chinese group reports that flubendazole, mebendazole and fenbendazole inhibit U87 and U251 glioblastoma cell proliferation at sub-micromolar IC50, arrest cells at G2/M via p53/p21/cyclin B1 and trigger pyroptosis. C2/C3 Ren 2022. Study type: in vitro human glioblastoma cell lines (U87, U251); N/A; country China (Institute of Materia Medica, CAMS/PUMC, Beijing); 0.125-0.5 μM; funder: not listed in the PubMed record; conflicts: 'The authors declare no competing interests'; maker: not stated; comparator: other azole compounds and untreated cells. This is the peer-reviewed glioblastoma paper behind the book's GBM claims; it is a cell study, not a ketogenic-diet study. Also filed as FBC-18, FBA-19, FBC-04 (claims C1, C2, C3, C4). Study type: lab.